---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-031241"
form_type: "8-K"
ticker: "INIS"
cik: "0001038277"
company_name: "RADNOSTIX INC"
filed_at: "2025-10-17T23:59:59+00:00"
generated_at: "2026-05-17T03:20:56.666736+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# International Isotopes CEO Bagerdjian signs 5-year employment agreement; Dr. Fu appointed to board

## Summary
- CEO Shahe Bagerdjian's base salary set at $314K with automatic 5% annual increases through 2030 and up to $250K in milestone raises based on quarterly revenue hitting $3.75M–$25M.
- Bagerdjian awarded 37.5M RSUs vesting in tranches at share prices of $0.10 to $0.30 over 60 consecutive calendar days; immediate vesting upon termination without cause or change of control.
- Dr. Duke W. Fu, nuclear pharmacist executive, appointed to board and audit committee; receives 250K RSUs annually.
- Bylaws amended: clarify special meeting business, add advance notice for shareholder proposals and director nominations, allow advisory directors, and update indemnification/insurance provisions.

## SEC filing metadata
- accession: 0001437749-25-031241
- form_type: 8-K
- ticker: INIS
- cik: 0001038277
- company_name: RADNOSTIX INC
- filed_at: 2025-10-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1038277/000143774925031241/0001437749-25-031241-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1038277/000143774925031241/inis20251016_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-031241
- JSON: https://secwatch.observer/filing/0001437749-25-031241.json
- Plain text: https://secwatch.observer/filing/0001437749-25-031241.txt

## Key facts
- Governance Changes
  RADNOSTIX INC: Amended bylaws to revise special meeting procedures, add advance notice requirements for business and director nominations, add advisory director provisions, revise written consent by shareholders, and add sections on indemnification and insurance (effective 2025-10-14).
  - Change: bylaw amendment
  - Effective: 2025-10-14
  source text: On October 14, 2025, the Board approved changes to the Company’s bylaws (the “Bylaws”), which are summarized below, and which are attached in full as an exhibit hereto.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1038277/000143774925031241/0001437749-25-031241-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.